These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 25179834)
1. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability. Barman-Aksözen J; Minder EI; Schubiger C; Biolcati G; Schneider-Yin X Blood Cells Mol Dis; 2015 Jan; 54(1):71-7. PubMed ID: 25179834 [TBL] [Abstract][Full Text] [Related]
2. Delta-aminolevulinic acid synthase 2 expression in combination with iron as modifiers of disease severity in erythropoietic protoporphyria. Barman-Aksözen J; Halloy F; Iyer PS; Schümperli D; Minder AE; Hall J; Minder EI; Schneider-Yin X Mol Genet Metab; 2019 Nov; 128(3):304-308. PubMed ID: 31076252 [TBL] [Abstract][Full Text] [Related]
3. Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria. Delaby C; Lyoumi S; Ducamp S; Martin-Schmitt C; Gouya L; Deybach JC; Beaumont C; Puy H Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):45-52. PubMed ID: 19268001 [TBL] [Abstract][Full Text] [Related]
4. Strong correlation of ferrochelatase enzymatic activity with Mitoferrin-1 mRNA in lymphoblasts of patients with protoporphyria. Phillips J; Farrell C; Wang Y; Singal AK; Anderson K; Balwani M; Bissell M; Bonkovsky H; Seay T; Paw B; Desnick R; Bloomer J Mol Genet Metab; 2019 Nov; 128(3):391-395. PubMed ID: 30391163 [TBL] [Abstract][Full Text] [Related]
5. Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity. Barman-Aksoezen J; Girelli D; Aurizi C; Schneider-Yin X; Campostrini N; Barbieri L; Minder EI; Biolcati G J Inherit Metab Dis; 2017 May; 40(3):433-441. PubMed ID: 28185024 [TBL] [Abstract][Full Text] [Related]
6. Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria. Di Pierro E; Granata F; De Canio M; Rossi M; Ricci A; Marcacci M; De Luca G; Sarno L; Barbieri L; Ventura P; Graziadei G Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054318 [TBL] [Abstract][Full Text] [Related]
10. Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice. Barman-Aksözen J; C Wiek P; Bansode VB; Koentgen F; Trüb J; Pelczar P; Cinelli P; Schneider-Yin X; Schümperli D; Minder EI Dis Model Mech; 2017 Mar; 10(3):225-233. PubMed ID: 28093505 [TBL] [Abstract][Full Text] [Related]
11. Mild iron deficiency does not ameliorate the phenotype of a murine erythropoietic protoporphyria model. Schmidt PJ; Hollowell ML; Fitzgerald K; Butler JS; Fleming MD Am J Hematol; 2020 May; 95(5):492-496. PubMed ID: 31990410 [TBL] [Abstract][Full Text] [Related]
12. Biochemical abnormality in erythropoietic protoporphyria: cause and consequences. Bloomer JR; Wang Y; Singhal A; Risheg H J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S36-40. PubMed ID: 16819399 [TBL] [Abstract][Full Text] [Related]
13. hem6: an ENU-induced recessive hypochromic microcytic anemia mutation in the mouse. Tian M; Campagna DR; Woodward LS; Justice MJ; Fleming MD Blood; 2008 Nov; 112(10):4308-13. PubMed ID: 18780836 [TBL] [Abstract][Full Text] [Related]
14. The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria. Wang P; Sachar M; Lu J; Shehu AI; Zhu J; Chen J; Liu K; Anderson KE; Xie W; Gonzalez FJ; Klaassen CD; Ma X Sci Adv; 2019 Sep; 5(9):eaaw6127. PubMed ID: 31555729 [TBL] [Abstract][Full Text] [Related]
15. Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. Parker CJ; Desnick RJ; Bissel MD; Bloomer JR; Singal A; Gouya L; Puy H; Anderson KE; Balwani M; Phillips JD Mol Genet Metab; 2019 Nov; 128(3):309-313. PubMed ID: 31395332 [TBL] [Abstract][Full Text] [Related]
16. Congenital erythropoietic porphyria and erythropoietic protoporphyria: Identification of 7 uroporphyrinogen III synthase and 20 ferrochelatase novel mutations. Weiss Y; Balwani M; Chen B; Yasuda M; Nazarenko I; Desnick RJ Mol Genet Metab; 2019 Nov; 128(3):358-362. PubMed ID: 30454868 [TBL] [Abstract][Full Text] [Related]
17. Heme Biosynthetic Gene Expression Analysis With dPCR in Erythropoietic Protoporphyria Patients. Granata F; Brancaleoni V; Barman-Aksözen J; Scopetti M; De Luca G; Fustinoni S; Motta I; Di Pierro E; Graziadei G Front Physiol; 2022; 13():886194. PubMed ID: 35923227 [No Abstract] [Full Text] [Related]
18. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. Lyoumi S; Abitbol M; Andrieu V; Henin D; Robert E; Schmitt C; Gouya L; de Verneuil H; Deybach JC; Montagutelli X; Beaumont C; Puy H Blood; 2007 Jan; 109(2):811-8. PubMed ID: 17003376 [TBL] [Abstract][Full Text] [Related]
19. Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. Balwani M; Doheny D; Bishop DF; Nazarenko I; Yasuda M; Dailey HA; Anderson KE; Bissell DM; Bloomer J; Bonkovsky HL; Phillips JD; Liu L; Desnick RJ; Mol Med; 2013 Apr; 19(1):26-35. PubMed ID: 23364466 [TBL] [Abstract][Full Text] [Related]
20. Neonatal bone marrow transplantation prevents liver disease in a murine model of erythropoietic protoporphyria. Duchartre Y; Petit N; Moya C; Lalanne M; Dubus P; Verneuil Hd; Moreau-Gaudry F; Richard E J Hepatol; 2011 Jul; 55(1):162-70. PubMed ID: 21145811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]